Inhibikase Therapeutics (IKT) Net Income towards Common Stockholders (2020 - 2024)
Historic Net Income towards Common Stockholders for Inhibikase Therapeutics (IKT) over the last 5 years, with Q4 2024 value amounting to -$12.9 million.
- Inhibikase Therapeutics' Net Income towards Common Stockholders fell 19359.61% to -$12.9 million in Q4 2024 from the same period last year, while for Sep 2025 it was -$12.9 million, marking a year-over-year increase of 3556.25%. This contributed to the annual value of -$28.6 million for FY2024, which is 4230.64% down from last year.
- Per Inhibikase Therapeutics' latest filing, its Net Income towards Common Stockholders stood at -$12.9 million for Q4 2024, which was down 19359.61% from -$5.8 million recorded in Q3 2024.
- In the past 5 years, Inhibikase Therapeutics' Net Income towards Common Stockholders registered a high of -$421869.0 during Q2 2020, and its lowest value of -$12.9 million during Q4 2024.
- Over the past 5 years, Inhibikase Therapeutics' median Net Income towards Common Stockholders value was -$4.6 million (recorded in 2022), while the average stood at -$4.2 million.
- In the last 5 years, Inhibikase Therapeutics' Net Income towards Common Stockholders plummeted by 56674.67% in 2021 and then skyrocketed by 1857.13% in 2024.
- Inhibikase Therapeutics' Net Income towards Common Stockholders (Quarter) stood at -$1.2 million in 2020, then crashed by 317.36% to -$5.0 million in 2021, then rose by 14.02% to -$4.3 million in 2022, then decreased by 1.58% to -$4.4 million in 2023, then plummeted by 193.6% to -$12.9 million in 2024.
- Its Net Income towards Common Stockholders stands at -$12.9 million for Q4 2024, versus -$5.8 million for Q3 2024 and -$5.1 million for Q2 2024.